Literature DB >> 17196868

Extra-skeletal effects of bisphosphonates.

Addolorata Corrado1, Nella Santoro, Francesco Paolo Cantatore.   

Abstract

Bisphosphonates are pharmacological agents which are currently used both in osteoporosis than in other pathological conditions characterised by an increased bone resorption, such as Paget's disease of bone, malign hypocalcaemia during myeloma, osteolytic bone metastasis and fibrous dysplasia of bone. The most important biological effect of bisphosphonates is the reduction of bone remodelling through the inhibition of osteoclastic activity, but there are many clinical and experimental evidences of extra-skeletal biological effects of bisphosphonates. It has been shown that bisphosphonates exert their effects not only on bone tissue cells, but also on those of the immune system with an "immuno-modulating" effect, influencing the production of pro- and anti-inflammatory cytokines and changing the molecular expression involved in the immune processes and anti-inflammatory response. Although the available data are conflicting, there are several reports concerning the beneficial effects of bisphosphonates in controlling the progression of chronic joint inflammatory diseases, suggesting a wider use for these therapeutic agents in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196868     DOI: 10.1016/j.jbspin.2006.06.005

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  22 in total

Review 1.  The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.

Authors:  Sammy Elmariah; Emile R Mohler
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

2.  Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).

Authors:  Sammy Elmariah; Joseph A C Delaney; Kevin D O'Brien; Matthew J Budoff; Jens Vogel-Claussen; Valentin Fuster; Richard A Kronmal; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2010-11-16       Impact factor: 24.094

3.  Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate.

Authors:  Toni Hospach; Micha Langendoerfer; Tekla von Kalle; Jan Maier; Guenther E Dannecker
Journal:  Eur J Pediatr       Date:  2010-03-27       Impact factor: 3.183

4.  Myocardial infarction risk among patients with fractures receiving bisphosphonates.

Authors:  Cory B Pittman; Lisa A Davis; Angelique L Zeringue; Liron Caplan; Kent R Wehmeier; Jeffrey F Scherrer; Hong Xian; Francesca E Cunningham; Jay R McDonald; Alexis Arnold; Seth A Eisen
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

5.  Exercise and zoledronic acid on lipid profile and bone remodeling in ovariectomized rats: a paradoxical negative association?

Authors:  E Lespessailles; C Jaffré; G Y Rochefort; E Dolléans; C L Benhamou; D Courteix
Journal:  Lipids       Date:  2010-03-13       Impact factor: 1.880

6.  Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis.

Authors:  Liu Zhang; Hongyu Hu; Faming Tian; Huiping Song; Yingze Zhang
Journal:  Clin Exp Med       Date:  2011-02-09       Impact factor: 3.984

7.  Medication persistence in older women with osteoporosis: a pilot study.

Authors:  C Gillette; D M Howerton; B D Williams; M A Mahmood
Journal:  Osteoporos Int       Date:  2015-07-21       Impact factor: 4.507

8.  Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.

Authors:  Pilar Peris; Elizabeth J Atkinson; Mario Gössl; Trevor L Kane; Louise K McCready; Amir Lerman; Sundeep Khosla; Ulrike I McGregor
Journal:  Mayo Clin Proc       Date:  2012-12-08       Impact factor: 7.616

9.  Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.

Authors:  Ozan Yazici; Sercan Aksoy; Ozgul Ucar; Nuriye Ozdemir; Mevlut Demir; Mehmet Ali Nahit Sendur; Zafer Arik; Sebnem Yaman; Tulay Eren; Dogan Uncu; Nurullah Zengin
Journal:  Med Oncol       Date:  2013-05-21       Impact factor: 3.064

Review 10.  Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.

Authors:  Oscar Leonard; Jonas Spaak; David Goldsmith
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.